Could an arthritis drug ease tough schizophrenia symptoms?
NCT ID NCT07615075
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called mirikizumab, which is already approved for other conditions, in people with schizophrenia who have a specific immune marker (AGA IgG antibodies). The goal is to see if it can improve negative symptoms like lack of motivation and pleasure, as well as thinking problems. About 40 participants will receive either the drug or a placebo for 16 weeks, alongside their usual antipsychotic medication.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Maryland Psychiatric Research Center (MPRC) Outpatient Research Program (ORP); the MPRC Treatment Research Program (TRP)
Catonsville, Maryland, 21228, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Could a new pill for schizophrenia pass its first human test?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates